Specify a stock or a cryptocurrency in the search bar to get a summary
Cns Pharmaceuticals Inc
CNSPCNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas. Address: 2100 West Loop South, Houston, TX, United States, 77027
Analytics
WallStreet Target Price
0.5 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CNSP
Dividend Analytics CNSP
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CNSP
Stock Valuation CNSP
Financials CNSP
Results | 2019 | Dynamics |